Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

Cited by (967)

Items 201–300 of 967

1. CAR T‐cell therapy for pancreatic cancer
   Carl J. DeSelm, Zachary E. Tano, Anna M. Varghese, Prasad S. Adusumilli · 2017 · Journal of Surgical Oncology
2. Solid Tumors Challenges and New Insights of CAR T Cell Engineering
   Safa Tahmasebi, Reza Elahi, Abdolreza Esmaeilzadeh · 2019 · Stem Cell Reviews and Reports
3. Novel immune check point inhibiting antibodies in cancer therapy—Opportunities and challenges
   Yael Diesendruck, Itai Benhar · 2017 · Drug Resistance Updates
4. Monitoring of Regulatory T Cell Frequencies and Expression of CTLA-4 on T Cells, before and after DC Vaccination, Can Predict Survival in GBM Patients
   Brendan Fong, Richard M Jin, Xiaoyan Wang, Michael Safaee, Dominique N. Lisiero, Isaac Yang, Gang Li, Linda M. Liau, Robert Michael Prins · 2012 · PLoS ONE
5. The Role of Inflammation in Kidney Cancer
   Antonio Roma de Vivar Chevez, James Harold Finke, Ronald M. Bukowski · 2014 · Advances in experimental medicine and biology
6. Cancer immunotherapy: Strategies for personalization and combinatorial approaches
   Vishwanath Sathyanarayanan, Sattva Swarup Neelapu · 2015 · Molecular Oncology
7. Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer
   Hélène Péré, Corinne Tanchot, Jagadeesh Bayry, Magali Terme, Julien Taı̈eb, Cécile Badoual, Olivier Adotévi, Nathalie Merillon, Elie Marcheteau, Véronique Quillien et al. · 2012 · OncoImmunology
8. Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment
   Lucia Lisi, Pedro Miguel Lacal, Maria Martire, Pierluigi Navarra, Grazia Graziani · 2021 · Pharmacological Research
9. Microbiota-dependent activation of CD4 + T cells induces CTLA-4 blockade–associated colitis via Fcγ receptors
   Bernard C. Lo, Ilona Kryczek, Jiali Yu, Linda Vatan, Roberta Caruso, Masanori Matsumoto, Yosuke Sato, Michael H. Shaw, Naohiro Inohara, Yuying Xie et al. · 2024 · Science
10. Immunotherapy for Primary Brain Tumors: No Longer a Matter of Privilege
    Peter Edward Fecci, Amy B. Heimberger, John Howard Sampson · 2014 · Clinical Cancer Research
11. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV+ oral cancer
    Stephanie M Dorta-Estremera, Venkatesh L. Hegde, Ravaen Slay, Rachel Sun, Ananta V. Yanamandra, Courtney Nicholas, Sita M.K. Nookala, Gloria Sierra, Michael A. Curran, K. Jagannadha Sastry · 2019 · Journal for ImmunoTherapy of Cancer
12. Maraviroc decreases CCL8-mediated migration of CCR5+regulatory T cells and reduces metastatic tumor growth in the lungs
    Elizabeth C. Halvorsen, Melisa J. Hamilton, A. Young, Brennan J. Wadsworth, Nancy E. LePard, H. N. Lee, Natalie S. Firmino, Jenna L. Collier, Kevin L. Bennewith · 2016 · OncoImmunology
13. Treg Fragility: A Prerequisite for Effective Antitumor Immunity?
    Overacre-Delgoffe, Abigail E., Vignali, Dario A.A. · 2018 · Cancer Immunology Research
14. Progress and opportunities for enhancing the delivery and efficacy of checkpoint inhibitors for cancer immunotherapy
    David Mark Francis, Susan Napier Thomas · 2017 · Advanced Drug Delivery Reviews
15. The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition
    Gilda Varricchi, Stefania Loffredo, Giancarlo Marone, Luca Modestino, Poupak Fallahi, Silvia Martina Ferrari, Amato de Paulis, Alessandro Antonelli, Maria Rosaria Galdiero · 2019 · International Journal of Molecular Sciences
16. Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management
    Yuwen Zhou, Yajuan Zhu, Man‐Ni Wang, Yao Xie, Chao-Yue Chen, Tao Zhang, Fan Xia, Zhenyu Ding, Jiyan Liu · 2019 · Frontiers in Pharmacology
17. MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways
    Arefeh Zabeti Touchaei, Sogand Vahidi · 2024 · Cancer Cell International
18. Remodeling the tumor microenvironment by oncolytic viruses: beyond oncolysis of tumor cells for cancer treatment
    Lihong Wang, Louisa S. Chard, Zhenguo Cheng, Yaohe Wang · 2022 · Journal for ImmunoTherapy of Cancer
19. Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer
    Christoph Carl Zielinski, Sylvia Knapp, Céline Mascaux, Fred R. Hirsch · 2013 · Annals of Oncology
20. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells
    Themis Alissafi, Aikaterini Hatzioannou, A.I. Legaki, Athina Varveri, Panayotis Verginis · 2019 · Journal of Autoimmunity
21. A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates
    Caroline Jochéms, Jo Anne Tucker, Kwong-Yok Tsang, Ravi Amrit Madan, William L. Dahut, David J. Liewehr, Seth M. Steinberg, James L. Gulley, Jeffrey Schlom · 2014 · Cancer Immunology Immunotherapy
22. Cutting Edge: CTLA-4 on Effector T Cells Inhibits In Trans
    Emily Corse, James Patrick Allison · 2012 · The Journal of Immunology
23. CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains
    Satoshi Shiina, Masasuke Ohno, Fumiharu Ohka, Shunichiro Kuramitsu, Akane Yamamichi, Akira Kato, Kazuya Motomura, Kuniaki Tanahashi, Takashi Yamamoto, Reiko Watanabe et al. · 2016 · Cancer Immunology Research
24. Renal effects of immune checkpoint inhibitors
    Hassan Izzedine, Christine Mateus, C. Boutros, Caroline Robert, Philippe Rouvier, Zahir Amoura, Alexis Mathian · 2016 · Nephrology Dialysis Transplantation
25. Immune Checkpoint Blockade
    Jarushka Naidoo, David B. Page, Jedd D. Wolchok · 2014 · Hematology/Oncology Clinics of North America
26. Immunotherapy of cancers comes of age
    Hila Yousefi, Jianda D. Yuan, Mahsa Keshavarz‐Fathi, Joseph F. Murphy, Nima Rezaei · 2017 · Expert Review of Clinical Immunology
27. Protamine-Based Strategies for RNA Transfection
    Jarzebska, Natalia Teresa, Mellett, Mark, Frei, Julia, Kündig, Thomas M., Pascolo, Steve · 2021 · Pharmaceutics
28. The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer
    Alemohammad, Hajar, Najafzadeh, Basira, Asadzadeh, Zahra, Baghbanzadeh, Amir, Ghorbaninezhad, Farid, Najafzadeh, Arezoo, Safarpour, Hossein, Bernardini, Renato, Brunetti, Oronzo, Sonnessa, Margherita et al. · 2022 · Biomedicine & Pharmacotherapy
29. Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy
    Anna Śledzińska, Laurie Menger, Katharina F. Bergerhoff, Karl S. Peggs, Sergio A. Quezada · 2015 · Molecular Oncology
30. The application of nanotechnology in immune checkpoint blockade for cancer treatment
    Huan Deng, Zhiping Zhang · 2018 · Journal of Controlled Release
31. RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer
    Elizabeth Stephanie Ahern, Heidi Harjunpää, Jake S. O’Donnell, Stacey M. Allen, William C. Dougall, Michele W.L. Teng, Mark John Smyth · 2018 · OncoImmunology
32. Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment
    Amblessed E. Onuma, Hongji Zhang, Hai Huang, Terence Marques Williams, Anne M. Noonan, Allan Tsung · 2020 · Gene Expression
33. Fcγ receptors and immunomodulatory antibodies in cancer
    Felipe Gálvez‐Cancino, Alexander P. Simpson, Cristóbal Costoya, Ignacio Garcia Matos, Danwen Qian, Karl S. Peggs, Kevin Litchfield, Sergio A. Quezada · 2023 · Nature reviews. Cancer
34. Maintenance DNA methylation is essential for regulatory T cell development and stability of suppressive function
    Kathryn A. Helmin, Luisa Morales‐Nebreda, Manuel A. Torres Acosta, Kishore Reddy Anekalla, Shang-Yang Chen, Hiam Abdala‐Valencia, Yuliya Politanska, Paul Cheresh, Mahzad Akbarpour, Elizabeth M. Steinert et al. · 2020 · Journal of Clinical Investigation
35. Regulatory T cells infiltrate the tumor-induced tertiary lymphoïd structures and are associated with poor clinical outcome in NSCLC
    Priyanka Devi-Marulkar, Solène Fastenackels, Pierre Karapentiantz, Jérémy Goc, Claire Germain, Hélène Kaplon, Samantha Knockaert, Daniel Olive, Marylou Panouillot, Pierre Validire et al. · 2022 · Communications Biology
36. Resistance to CTLA-4 checkpoint inhibition reversed through selective elimination of granulocytic myeloid cells
    Paul E. Clavijo, E. Moore, Jian-Hong Chen, Ruth J. Davis, J. Friedman, Y. Kim, C. Van Waes, Zhong Chen, C. Allen · 2017 · OncoTarget
37. T cell profiling reveals high CD4+CTLA-4+ T cell frequency as dominant predictor for survival after Prostate GVAX/ipilimumab treatment
    Saskia J A M Santegoets, Anita G.M. Stam, Sinéad M. Lougheed, Helen E. Gall, Petra E.T. Scholten, Martine Reijm, Karin U. Jooss, Natalie Sacks, Kristen M. Hege, Israel Lowy et al. · 2012 · Cancer Immunology Immunotherapy
38. Therapeutic Antibodies Against Cancer
    Mark J. Adler, Dimiter Stanchev Dimitrov · 2012 · Hematology/Oncology Clinics of North America
39. The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1
    Zhaohui Jin, Harry H. Yoon · 2016 · Journal of Gastrointestinal Oncology
40. Immune-Related Adverse Events Due to Cancer Immunotherapy: Immune Mechanisms and Clinical Manifestations
    Silvia Casagrande, Giulia Boscato Sopetto, Giovanni Bertalot, Roberto Bortolotti, Vito Racanelli, Orazio Caffo, Bruno Giometto, Alvise Berti, Antonello Veccia · 2024 · Cancers
41. Selective CD28 Blockade Attenuates Acute and Chronic Rejection of Murine Cardiac Allografts in a CTLA-4-Dependent Manner
    T. Zhang, S. Fresnay, Emily E. Welty, Nitin Sangrampurkar, E. Rybak, H. Zhou, X. Cheng, Q. Feng, C. Avon, Amal Laaris et al. · 2011 · American Journal of Transplantation
42. Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy
    Kelly Kersten, Camilla Salvagno, Karin E. de Visser · 2015 · Frontiers in Immunology
43. The Immunobiology of Kidney Cancer
    Charles G. Drake, Mark N. Stein · 2018 · Journal of Clinical Oncology
44. The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment
    Patrizia Leone, Antonio Giovanni Solimando, Rossella Fasano, Antonella Argentiero, Eleonora Malerba, Alessio Buonavoglia, L. Lupo, Vallì De Re, Nicola Silvestris, Vito Racanelli · 2021 · Vaccines
45. Effects of BRAF Mutations and BRAF Inhibition on Immune Responses to Melanoma
    Kristina M. Ilieva, Isabel Corrêa, Debra Hannah Josephs, Panagiotis Karagiannis, Isioma U. Egbuniwe, M Cafferkey, James F. Spicer, Mark Harries, Frank Oliver Nestle, Katie E. Lacy et al. · 2014 · Molecular Cancer Therapeutics
46. Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice
    Elizabeth Stephanie Ahern, Heidi Harjunpää, Deborah Sim Barkauskas, Stacey M. Allen, Kazuyoshi Takeda, Hideo Yagita∥, David Wyld, William C. Dougall, Michele W.L. Teng, Mark John Smyth · 2017 · Clinical Cancer Research
47. Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo
    Linda C. Sandin, Fredrik Eriksson, Peter Ellmark, Angelica Loskog, Thomas H. Tötterman, Sara M. Mangsbo · 2014 · OncoImmunology
48. Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach
    Miguel López de Rodas, María Villalba-Esparza, Miguel F. Sanmamed, Lieping Chen, David L. Rimm, Kurt Alex Schalper · 2025 · Nature Reviews Clinical Oncology
49. Cutting Edge: Cell-Extrinsic Immune Regulation by CTLA-4 Expressed on Conventional T Cells
    Chun Jing Wang, Rupert Kenefeck, Lukasz Wardzinski, Kesley Attridge, Claire N. Manzotti, Emily M. Schmidt, Omar Qureshi, David Michael Sansom, Lucy S. K. Walker · 2012 · The Journal of Immunology
50. Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy
    Xiaofeng Chang, Xiaofeng Lu, Jinhe Guo, Gao‐Jun Teng · 2018 · Cancer Treatment Reviews
51. Tumor regulation of the tissue environment in the liver
    Tobias Eggert, Tim F. Greten · 2017 · Pharmacology & Therapeutics
52. How to improve the immunogenicity of chemotherapy and radiotherapy
    Yuting Ma, Rosa Conforti, Laetitia Aymeric, Clara Locher, Oliver Kepp, Guido Kroemer, Laurence Zitvogel · 2011 · Cancer and Metastasis Reviews
53. Tumour cell‐intrinsic CTLA 4 regulates PD ‐L1 expression in non‐small cell lung cancer
    Huijun Zhang, Pranabananda Dutta, Jinguo Liu, Nafiseh Sabri, Yuanlin Song, Willis X. Li, Jinghong Li · 2018 · Journal of Cellular and Molecular Medicine
54. Immunotherapy for platinum-resistant ovarian cancer
    Giorgio Bogani, Salvatore Lopez, Mara Mantiero, Monika Ducceschi, Sara Bosio, Simona Ruisi, Giuseppe Sarpietro, Rocco Guerrisi, Claudia Brusadelli, Andrea Dell'acqua et al. · 2020 · Gynecologic Oncology
55. Immune evasion mechanisms in acute myeloid leukemia: A focus on immune checkpoint pathways
    Saeid Taghiloo, Hossein Asgarian‐Omran · 2020 · Critical Reviews in Oncology/Hematology
56. The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy
    Bonnie L. Russell, Selisha Ann Sooklal, Sibusiso Tebogo Malindisa, Lembelani Jonathan Daka, Monde McMillan Ntwasa · 2021 · Frontiers in Oncology
57. The Risk of Diarrhea and Colitis in Patients With Advanced Melanoma Undergoing Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis
    Parul Tandon, Samuel Bourassa‐Blanchette, Kirles Bishay, Simon Parlow, Scott Andrew Laurie, Jeffrey D. McCurdy · 2018 · Journal of Immunotherapy
58. Immunotherapy in pancreatic cancer treatment: a new frontier
    Komal Thind, Leslie Jane Padrnos, Ramesh K. Ramanathan, Mitesh J. Borad · 2016 · Therapeutic Advances in Gastroenterology
59. Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies
    Jay Alan Fishman, John I Hogan, Marcela Valderrama Maus · 2018 · Clinical Infectious Diseases
60. Combination Therapy of Established Tumors by Antibodies Targeting Immune Activating and Suppressing Molecules
    Kazuyoshi Takeda, Yuko Kojima, Tomoyasu Uno, Yoshihiro Hayakawa, Michele W.L. Teng, Hirohisa Yoshizawa, Hideo Yagita∥, Fumitake Gejyo, Ko Okumura, Mark John Smyth · 2010 · The Journal of Immunology
61. Checkpoint inhibitor-induced liver injury: A novel form of liver disease emerging in the era of cancer immunotherapy
    Yoh Zen, Matthew M. Yeh · 2019 · Seminars in Diagnostic Pathology
62. Immune Modulation by Chemotherapy or Immunotherapy to Enhance Cancer Vaccines
    Genevieve M. Weir, Robert Liwski, Marc Mansour · 2011 · Cancers
63. Immune checkpoint therapy for pancreatic cancer
    Henrik Johansson, Roland E. Andersson, Monika Posaric Bauden, Sarah Hammes, Stefan Holdenrieder, Daniel Ansari · 2016 · World Journal of Gastroenterology
64. Neoepitopes as Cancer Immunotherapy Targets: Key Challenges and Opportunities
    Cory A Brennick, Mariam Mathew George, William L. Corwin, Pramod Kumar Srivastava, Hakimeh Ebrahimi-Nik · 2017 · Immunotherapy
65. Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy
    Wen Cheng, Dian Fu, Feng Xu, Zhengyu Zhang · 2018 · Oncogenesis
66. CTLA-4 (CD152): A versatile receptor for immune-based therapy
    Holger Lingel, Monika Christine Brunner-Weinzierl · 2019 · Seminars in Immunology
67. Cyclic AMP underpins suppression by regulatory T cells
    Josef Bodor, Tobias Bopp, Martin Vaeth, Matthias Klein, Edgar Serfling, Thomas Hünig, Christian Becker, Hansjörg Schild, Edgar Schmitt · 2012 · European Journal of Immunology
68. Cytotoxic T Lymphocyte Antigen-4 Blockade Enhances Antitumor Immunity by Stimulating Melanoma-Specific T-cell Motility
    Tsvetelina Pentcheva‐Hoang, Tyler R. Simpson, Welby Montalvo-Ortiz, James Patrick Allison · 2014 · Cancer Immunology Research
69. Preclinical Efficacy and Immunological Safety of FR104, an Antagonist Anti-CD28 Monovalent Fab′ Antibody
    Nicolas Poirier, Caroline Mary, Nahzli Dilek, Jérémy Hervouet, David Minault, Gilles Blancho, Bernard Vanhove · 2012 · American Journal of Transplantation
70. Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice
    Stefanie N. Linch, Melissa J. Kasiewicz, Michael J. McNamara, Ian Hilgart-Martiszus, Mohammad E Farhad, William L. Redmond · 2016 · Proceedings of the National Academy of Sciences
71. The role of regulatory T cells in the pathogenesis and treatment of prostate cancer
    Vahid Karpisheh, Seyedeh Mahboubeh Mousavi, Parinaz Naghavi Sheykholeslami, Mehrdad Fathi, Mehran Mohammadpour Saray, Leili Aghebati Maleki, Reza Jafari, Naime Majidi Zolbanin, Farhad Jadidi‐Niaragh · 2021 · Life Sciences
72. Targeting regulatory T cells to improve vaccine immunogenicity in early life
    Jorjoh Ndure, Katie L. Flanagan · 2014 · Frontiers in Microbiology
73. Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach
    Chang-Gon Kim, Yun Beom Sang, Ji Hyun Lee, Hong Jae Chon · 2021 · International Journal of Molecular Sciences
74. Immunosuppressive Microenvironment in Neuroblastoma
    Vito Pistoia, Fabio Morandi, Giovanna Bianchi, Annalisa Pezzolo, Ignazia Prigione, Lizzia Raffaghello · 2013 · Frontiers in Oncology
75. Chimeric Antigen Receptor-Engineered T Cells for the Treatment of Metastatic Prostate Cancer
    Victoria Hillerdal, Magnus Essand · 2015 · BioDrugs
76. Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer
    Maureen L. Drakes, Swati Mehrotra, Monica Aldulescu, Ronald K. Potkul, Yueying Liu, Anne Grisoli, Cara Joyce, Timothy E. O’Brien, Mary Sharon Stack, Patrick J. Stiff · 2018 · Journal of Ovarian Research
77. CpG Oligodeoxynucleotides for Anticancer Monotherapy from Preclinical Stages to Clinical Trials
    Zhongkun Zhang, Jimmy Chun‐Tien Kuo, Siyu Yao, Chi Zhang, Hira Khan, Robert J. Lee · 2021 · Pharmaceutics
78. TLR1/2 ligand enhances antitumor efficacy of CTLA-4 blockade by increasing intratumoral Treg depletion
    Naveen Sharma, Jean Vacher, James Patrick Allison · 2019 · Proceedings of the National Academy of Sciences
79. CTLA-4 Blockade Expands Infiltrating T Cells and Inhibits Cancer Cell Repopulation during the Intervals of Chemotherapy in Murine Mesothelioma
    Licun Wu, Zhihong Yun, Tetsuzo Tagawa, Katrina Rey‐McIntyre, Marc E. de Perrot · 2012 · Molecular Cancer Therapeutics
80. Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations.
    Alexander Grenander Raufi, Samuel Jacob Klempner · 2015 · Europe PMC (PubMed Central)
81. Clinical Development of Immune Checkpoint Inhibitors
    Ayumu Ito, Shunsuke Kondo, Kohei Tada, Shigehisa Kitano · 2015 · BioMed Research International
82. Aberrations in DNA repair pathways in cancer and therapeutic significances
    Akira Motegi, Mitsuko Masutani, Kenichi Yoshioka, Tadayoshi Bessho · 2019 · Seminars in Cancer Biology
83. Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929)
    Diane M. Da Silva, Danielle M. Enserro, Jyoti Mayadev, Joseph G. Skeate, Koji Matsuo, Huyen Q. Pham, Heather A. Lankes, Katherine Marie Moxley, Sharad A. Ghamande, Yvonne Gail Lin et al. · 2020 · Clinical Cancer Research
84. Immune Checkpoint Inhibitors and Cardiac Toxicity in Patients Treated for Non-Small Lung Cancer: A Review
    Grzegorz Sławiński, Anna Wrona, Alicja Dąbrowska-Kugacka, Grzegorz Raczak, Ewa Lewicka · 2020 · International Journal of Molecular Sciences
85. Rationale for Chemotherapy, Immunotherapy, and Checkpoint Blockade in SCLC: Beyond Traditional Treatment Approaches
    David Robert Spigel, Mark A. Socinski · 2013 · Journal of Thoracic Oncology
86. Tremelimumab: A Review of Development to Date in Solid Tumors
    Ahmad A. Tarhini · 2013 · Immunotherapy
87. Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma
    Mark John Smyth, Hideo Yagita∥, Grant A. McArthur · 2014 · Journal of Clinical Oncology · Retracted
88. Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy
    Julie Marie Collins, Jason Mark Redman, James L. Gulley · 2018 · Expert Review of Vaccines
89. Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management
    Paola Savoia, Chiara Astrua, Paolo Fava · 2016 · Human Vaccines & Immunotherapeutics
90. Cytotoxic T lymphocyte antigen-4 expression in esophageal carcinoma: implications for prognosis
    Xiao-Fei Zhang, Ke Pan, Desheng Weng, Chang-Long Chen, Qi-jing Wang, Jing-Jing Zhao, Qiuzhong Pan, Qing Liu, Shan-Shan Jiang, Yong-Qiang Li et al. · 2016 · Oncotarget
91. Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma
    Mark Cameron Mochel, Michael E. Ming, Sotonye E. Imadojemu, Tara C. Gangadhar, Lynn Mara Schuchter, Rosalie Elenitsas, Aimee S. Payne, Emily Y. Chu · 2016 · Journal of Cutaneous Pathology
92. CTLA-4 blockade and the renaissance of cancer immunotherapy
    Simone Mocellin M. D, Donato Nitti · 2013 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
93. New Insights into the Role of the Immune Microenvironment in Breast Carcinoma
    Luis de la Cruz‐Merino, Antonio Barco-Sánchez, Fernando Henao, Esteban Nogales Fernández, Ana Vallejo Benítez, Javier Brugal Molina, Antonio Martínez-Peinado, Ana Grueso López, Manuel Ruíz Borrego, Manuel Codes Manuel de Villena et al. · 2013 · Clinical and Developmental Immunology
94. Low stromal Foxp3+ regulatory T-cell density is associated with complete response to neoadjuvant chemoradiotherapy in rectal cancer
    Melanie J. McCoy, Chris Hemmings, Timothy J. Miller, Stephanie J. Austin, Max Kishor Bulsara, Nikolajs Zeps, Anna K. Nowak, Richard Lake, Cameron F E Platell · 2015 · British Journal of Cancer
95. Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer
    Sevda Jafari, Ommoleila Molavi, Houman Kahroba, Mohammad Saeid Hejazi, Nasrin Maleki‐Dizaji, Siamak Barghi, Seyed Hossein Kiaie, Farhad Jadidi‐Niaragh · 2020 · Cellular and Molecular Life Sciences
96. Reprogramming the tumor microenvironment to enhance adoptive cellular therapy
    Paul A. Beavis, Clare Y. Slaney, Michael H. Kershaw, David E. Gyorki, Paul Joseph Neeson, Phillip Kevin Darcy · 2015 · Seminars in Immunology
97. Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma
    Veerendra Koppolu, VeneelaKrishna Rekha Vasigala · 2018 · Journal of Cancer Research and Therapeutics
98. Immune checkpoint inhibitors: new strategies to checkmate cancer
    Ruairí Wilson, Thomas R. Jeffry Evans, Alasdair R. Fraser, Robert J. B. Nibbs · 2017 · Clinical & Experimental Immunology
99. Toll‐like receptors: The role in bladder cancer development, progression and immunotherapy
    Solmaz Ohadian Moghadam, Mohammad Reza Nowroozi · 2019 · Scandinavian Journal of Immunology
100. Dual PD-1 and CTLA-4 checkpoint blockade promotes antitumor immune responses through CD4(+)Foxp3(-) cell-mediated modulation of CD103(+) dendritic cells
     Beavis, Paul A., Henderson, Melissa A., Giuffrida, Lauren, Davenport, Alexander J., Petley, Emma V., House, Imran G., Lai, Junyun, Sek, Kevin, Milenkovski, Nicole, John, Liza B. et al. · 2018 · Cancer Immunology Research